Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens. As he ...

Medical experts are urging a shift in how clinicians evaluate mental health, emphasizing that effective treatment for depression, anxiety, and cognitive decline must begin with sl ...

ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH. Darolutamide is associated ...

Intraoperative cesium-131 tile-based radiation therapy (TBRT) with GammaTile significantly improved local control, surgical bed recurrence-free survival (SB-RFS), and overall surv ...

While lifestyle alterations have been previously recommended to control potassium levels for some patients with hyperkalemia, ...

In HepG2.117 cells, ALG-001075 achieved HBV DNA EC50 0.64 nM, outperforming canocapavir (5.8 nM) and neracorvir (24 nM) with ...

Fee-for-service beneficiaries had higher BGP use than Medicare Advantage (25.8% vs 24.6%; AOR 1.08), indicating payer ...

Fragmented subspecialty care and underbuilt survivorship pathways risk overwhelming primary care as the survivor population ...

Teclistamab (Tecvayli; Johnson & Johnson) appears poised to move into earlier lines of care as a monotherapy, as bispecific antibodies made big news in the treatment of blood cancers and disorders on ...

Accelerating private equity “roll-up” consolidation can evade antitrust thresholds, and post-acquisition staffing reductions have been associated with higher hospital-acquired conditions, falls, ...

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes ...

This article provides a commentary on a news feature published on AJMC.com in 2025 titled “AI Seen as Key to Reducing Health Care Claim Denials, Survey Finds.” We read with interest a feature article ...